Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Eat in 8 hours, heal your liver? new study tests Time-Restricted diet for fatty liver

NCT ID NCT06705868

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether eating only during an 8-hour window each day (time-restricted eating) can help people with fatty liver disease (MASLD) lose weight and body fat. 150 adults will follow this eating pattern for 3 months, with some also limiting fruit and vegetable intake to daylight hours. Researchers will compare results to standard care to see if this approach improves liver health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Body mass index 25 (±0,5)-45(±0,5) kg/m2 2. Clinical diagnosis of MASLD, not excluding undiagnosed NASH or with NASH stage F0-F1 3. Self-reported habitual eating period more than or equal to 14 h per day, BUT NOT LESS. 4. Cyprus inhabitants of for at least 1 year 5. Registered to the National Health System of the Republic of Cyprus (Gesy Exclusion Criteria: 1. Night Shift worker 2. Fasting \>12-h/day more than once a week or \> once a week no food intake after 18:00 3. Co-existing causes of chronic liver disease according to standard diagnostic testing including, but not restricted to: 1. Positive hepatitis B surface antigen 2. Positive hepatitis C virus RNA 3. Suspicion of drug-induced liver disease 4. Alcoholic liver disease 5. Autoimmune hepatitis 6. Wilson's disease 7. Hemochromatosis 8. Primary biliary cholangitis or primary sclerosing cholangitis 9. Known or suspected hepatocellular carcinoma 4. Medications which cause liver disease or secondary hepatic steatosis (Tamoxifen, systemic corticosteroids, methotrexate, tetracycline, estrogens, valproic acid, and statin (registration is possible if statin is delivered in a consistent dosage within 12 weeks) 5. Current or recent history (\<5 years) of significant alcohol intake (\>30g of alcohol/ day or \>210g/week for men, \>20g of alcohol/day or \>140g/week for women) 6. Doctor diagnosed diabetes mellitus on insulin or sulfonylureas 7. Severe medical comorbidities \[ischemic heart disease, 3rd degree atrioventricular block, chronic obstructive pulmonary disease, severe hypertension (blood pressure \>200/120 mmHg)\] 8. Unstable weight (\>5% change in the last 2 months) or participation in a weight-loss program within the past 12 weeks 9. Sleep disorder (with a medical diagnosis) or individuals self-reporting sleep difficulties and poor sleep \[average sleep less than 6 consecutive hours or patients who systematically experience sleep interruption for more than 2 times each night (waking up for toilet use is not to be considered sleep interruption)\] 10. Individuals with food allergies (or hypersensitivity to the fruits and vegetables that will be selected for the study) 11. Systematic organic products consumers (defined as a self-reported usual consumption of more than 80% of their weekly fruits \& vegetables being organic) 12. Pregnant or trying to become pregnant or lactating women 13. People not in position to communicate in Greek or English language 14. Having metallic parts in the body.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASLD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Limassol General Hospital

    Limassol, 4159, Cyprus

More trials for these conditions

Other studies related to the condition(s) this trial covers.